Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 2 of the 40 sources its claims cite were checked for support.
Abstract
Context: Women with polycystic ovary syndrome (PCOS) have an increased risk of cardiovascular disease (CVD), and biomarkers can be used to detect early subclinical CVD. Midregional-pro-adrenomedullin (MR-proADM), midregional-pro-atrial natriuretic peptide (MR-proANP) and copeptin are all associated with CVD and part of the delicate system controlling fluid and hemodynamic homeostasis through vascular tonus and diuresis. The GLP-1 receptor agonist liraglutide, developed for treatment of type 2 diabetes (T2D), improves cardiovascular outcomes in patients with T2D including a decrease in particular MR-proANP. Objective: To investigate if treatment with liraglutide in women with PCOS reduces levels of the cardiovascular biomarkers MR-proADM, MR-proANP and copeptin. Methods: Seventy-two overweight women with PCOS were treated with 1.8 mg/day liraglutide or placebo for 26 weeks in a placebo-controlled RCT. Biomarkers, anthropometrics, insulin resistance, body composition (DXA) and visceral fat (MRI) were examined. Results: Baseline median (IQR) levels were as follows: MR-proADM 0.52 (0.45–0.56) nmol/L, MR-proANP 44.8 (34.6–56.7) pmol/L and copeptin 4.95 (3.50–6.50) pmol/L. Mean percentage differences (95% CI) between liraglutide and placebo group after treatment were as follows: MR-proADM −6% (−11 to 2, P = 0.058), MR-proANP −25% (−37 to −11, P = 0.001) and copeptin +4% (−13 to 25, P = 0.64). Reduction in MR-proANP concentration correlated with both increased heart rate and diastolic blood pressure in the liraglutide group. Multiple regression analyses with adjustment for BMI, free testosterone, insulin resistance, visceral fat, heart rate and eGFR showed reductions in MR-proANP to be independently correlated with an increase in the heart rate. Conclusion: In an RCT, liraglutide treatment in women with PCOS reduced levels of the cardiovascular risk biomarkers MR-proANP with 25% and MR-proADM with 6% (borderline significance) compared with placebo. The decrease in MR-proANP was independently associated with an increase in the heart rate.
Overview
CoChat Summary
TL;DR
In a 26-week placebo-controlled RCT in overweight women with PCOS, liraglutide reduced MR-proANP by 25% and showed a borderline 6% reduction in MR-proADM, with no change in copeptin. The MR-proANP reduction was independently associated with an increase in heart rate.
Key findings
- Baseline median (IQR) biomarker levels were MR-proADM 0.52 (0.45–0.56) nmol/L, MR-proANP 44.8 (34.6–56.7) pmol/L, and copeptin 4.95 (3.50–6.50) pmol/L.
- After treatment, mean percentage differences between liraglutide and placebo were MR-proADM −6% (95% CI −11 to 2, P = 0.058; table P = 0.057), MR-proANP −25% (95% CI −37 to −11, P = 0.001), and copeptin +4% (95% CI −13 to 25, P = 0.64).
- In the liraglutide group, ΔMR-proANP correlated inversely with Δheart rate (β −0.69, r 0.33, P = 0.03) and Δdiastolic blood pressure (β −0.89, r 0.34, P = 0.03); multiple regression adjusting for BMI, free testosterone, Matsuda index, VAT, heart rate, and eGFR showed ΔMR-proANP remained independently correlated with Δheart rate (β −0.77, s.e. 0.36, P = 0.045).
- Liraglutide treatment increased heart rate by 6 bpm (95% CI 2–10, P = 0.006) and reduced weight by 5.2 kg (95% CI 3.0–7.5, P < 0.001) versus placebo.
Methods
- Double-blind, placebo-controlled RCT (LIPT study): 72 overweight women with PCOS randomized 2:1 to 1.8 mg/day liraglutide or placebo for 26 weeks; inclusion required PCOS by Rotterdam criteria, BMI >25 kg/m² and/or insulin resistance, and non-hormonal contraception.
- Biomarkers MR-proADM, MR-proANP, and copeptin were measured by automated immunofluorescence assay; anthropometrics, DXA body composition, MRI visceral/subcutaneous fat, insulin resistance indices, and routine biochemistry were also assessed.
- A mixed model with repeated statement tested treatment-group differences over time; linear univariate and multiple regression analyses examined Δ biomarker associations in the liraglutide group.
Limitations
- The paper states that 24-h ambulatory blood pressure and heart rate recordings were not performed, which would have given more precise estimates.
- The paper states that the study may be underpowered for MR-proADM because the expected change was not met, and that biological/analytical variation means the small observed changes are less than suggested clinically relevant percent changes, weakening the results.
- The paper notes that natriuresis was not measured, and that BNP, galectin-3, and troponins were not measured; the text also makes evident that the cohort was relatively young and without overt CVD, which may limit detection of subclinical changes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
2 Valid · 0 Not valid · 27 Not checked · 34 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The three biomarkers have previously been evaluated in PCOS and healthy controls in cross-sectional studies, with contradicting results (13, 14, 15, 16, 17, 18).”
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Introduction
What the sources say
- Not checked yetcites [13] Ucar B Noyan V Caglayan O Yucel A Sagsoz N. Plasma adrenomedullin levels in patients with polycystic ovary syndrome. Fertility and Sterility 2006 86 942– 948. (10.1016/j.fertnstert.2006.02.119) 16963041 source
- Not checked yetcites [14] Sahin I Celik O Celik N Keskin L Dogru A Dogru I Yürekli M Yologlu S Adrenomedullin: possible predictor of insulin resistance in women with polycystic ovary syndrome. Journal of Endocrinological Investigation 2012 35 553– 556. (10.3275/7872) 21791966 doi:10.3275/7872
- Not checked yetcites [15] Lauria PBM Del Puerto HL Reis AM Candido AL Reis FM. Low plasma atrial natriuretic peptide: a new piece in the puzzle of polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2013 98 4882– 4889. (10.1210/jc.2013-2141) 24057296 source
- Not checked yetcites [16] Karbek B Ozbek M Karakose M Topaloglu O Bozkurt NC Cakır E Aslan MS Delibasi T Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. Journal of Ovarian Research 2014 7 31 (10.1186/1757-2215-7-31) 24628831 PMC3995558 source
- Not checked yetcites [17] Taskin MI Bulbul E Adali E Hismiogulları AA Inceboz U. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome. European Journal of Obstetrics and Gynecology and Reproductive Biology 2015 189 19– 23. (10.1016/j.ejogrb.2015.03.006) 25837320 source
- Partly supportedcites [18] Deveer M Deveer R Basaran O Turkcu UO Akbaba E Cullu N Turhan N Kucuk M Kasap B Serum copeptin, pentraxin 3, anti-mullerian hormone levels with echocardiography and carotid artery intima-media thickness in adolescents with polycystic ovary syndrome. Journal of Clinical Medicine Research 2015 7 989– 994. (10.14740/jocmr2375w) 26566413 PMC4625820 sourceExperimental — accuracy not yet measured
Our copy of Deveer et al. 2015 is itself a cross-sectional PCOS-vs-control study (Abstract Methods; Material and Methods) and it documents discordance in the copeptin literature: Karbek et al found copeptin elevated/correlated with insulin, HOMA-IR, TG, testosterone and CIMT, whereas 'In our study, copeptin was not correlated with fasting insulin, TG, testosterone levels, CIMT, HOMA-IR, and F-G score' (Discussion), concluding 'we failed to demonstrate the role of copeptin and PTX3 in PCOS'. However, the claim attributes contradicting cross-sectional evidence to three biomarkers, and MR-proADM and MR-proANP are not mentioned anywhere in our copy (searched: MR-proADM/mid-regional pro-adrenomedullin/MR-proANP, contradictory/inconclusive prior results) — the paper's other discordant markers are PTX3 and AMH, not the two adrenomedullin/atrial-natriuretic peptides. So only the copeptin element of the attributed point is supported. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ΔMR-proADM did not correlate significantly in univariate analysis with any of the tested parameters.”
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Results > Regression analyses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MR-proADM −6% (−11 to 2, P = 0.058)”
- Also stated in: § Biomarkers · hedged
“a trend in MR-proADM of −6% (95% CI −11 to 2, P = 0.057)”
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Biomarkers · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On average (95% CI), the liraglutide group lost 5.2 kg (3.0–7.5, P < 0.001) equal to 5.6% body weight as mean difference compared with placebo.”
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Results > Anthropometrics and body composition
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Multiple regression analyses with adjustment for BMI, free testosterone, insulin resistance, visceral fat, heart rate and eGFR showed reductions in MR-proANP to be independently correlated with an increase in the heart rate.”
- Also stated in: § Regression analyses · plain
“Multiple regression analyses with adjustment for BMI, free testosterone, Matsuda index, VAT, heart rate and eGFR showed ΔMR-proANP and heart rate to be independently correlated (Table 2).”
- Also stated in: § Regression analyses · plain
“ΔHeart rate | −0.77 (0.36) | 0.045”
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Abstract > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Regression analyses · plain
26 more claims
Create a free account to see all 63 claims and to verify the 38 references still open.
- Probably not a substantial claim. 25
- The quote only partly states this claim. 3
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some studies compared the liraglutide 1.8 mg/day vs. placebo for 26 weeks and demonstrated a greater efficacy in terms of reduction of body weight and waist circumference (WC) in the liraglutide group [54–56].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“A total of 72 women were randomized in a 2:1 ratio allocating 42 women to liraglutide treatment and 21 to placebo.”
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Results
Reported 72 · recomputed 63
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Abstract > Results
“MR-proADM −6% (−11 to 2, P = 0.058)”
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Results > Anthropometrics and body composition
“Ratio 0.94 (0.89–1.002)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Results > Regression analyses
“As ΔMR-proADM and copeptin did not change during the treatment period, regressions analyses were not performed.”
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Results > Regression analyses
“ΔMR-proADM did not correlate significantly in univariate analysis with any of the tested parameters.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Results > Anthropometrics and body composition
“| DXA fat mass (kg) | 35.9 ± 8.5 | −2.6 ± 0.5 | 35.7 ± 7.2 | 0.3 ± 0.7 | −2.8 (−4.6 to 1.1) | 0.002 |”
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Results > Anthropometrics and body composition
“We observed significant reductions in total fat and lean body mass as measured by DXA”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Results > Anthropometrics and body composition
“| MRI VAT (cm3) | 115.7 ± 51.4 (n = 44) | −17.2 ± 4.3 (n = 37) | 120.9 ± 42.3 (n = 23)”
§ Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS > Results
“allocating 42 women to liraglutide treatment and 21 to placebo”
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Impact of Obesity on Plasma Natriuretic Peptide Levels
Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Leip, E. P., Wilson, P. W. F., & Vasan, R. S. (2004) · Circulation · doi:10.1161/01.cir.0000112582.16683.ea · Cited by 1,022
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Adrenomedullin, a Multifunctional Regulatory Peptide*
Hinson, J. P., Kapas, S., & Smith, D. M. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0396 · Cited by 752
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay
Morgenthaler, N. G., Struck, J., Alonso, C., & Bergmann, A. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.051110 · Cited by 399
Plasma Copeptin and the Risk of Diabetes Mellitus
Enhörning, S., Wang, T. J., Nilsson, P. M., Almgren, P., Hedblad, B., Berglund, G., Struck, J., Morgenthaler, N. G., Bergmann, A., Lindholm, E., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.909663 · Cited by 299
Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296
Natriuretic peptides in cardiometabolic regulation and disease
Zois, N. E., Bartels, E. D., Hunter, I., Kousholt, B. S., Olsen, L. H., & Goetze, J. P. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.64 · Cited by 182
Influence of sex and hormone status on circulating natriuretic peptides
Lam, C. S. P., Cheng, S., Choong, K., Larson, M. G., Murabito, J. M., Newton-Cheh, C., Bhasin, S., McCabe, E. L., Miller, K. K., Redfield, M. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.03.042 · Cited by 181
Plasma Copeptin, A Unifying Factor behind the Metabolic Syndrome
Enhörning, S., Struck, J., Wirfält, E., Hedblad, B., Morgenthaler, N. G., & Melander, O. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2981 · Cited by 177
Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis.
Zhao, L., Zhu, Z., Lou, H., Zhu, G., Huang, W., Zhang, S., & Liu, F. (2016) · Oncotarget · doi:10.18632/oncotarget.9553 · Cited by 174
Lovshin, J. A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., & Drucker, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1958 · Cited by 168
Skov, J., Pedersen, M., Holst, J. J., Madsen, B., Goetze, J. P., Rittig, S., Jonassen, T., Frøkiær, J., Dejgaard, A., & Christiansen, J. S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12651 · Cited by 128
Adrenomedullin and cardiovascular diseases
Wong, H. K., Cheung, T. T., & Cheung, B. M. Y. (2012) · JRSM Cardiovascular Disease · doi:10.1258/cvd.2012.012003 · Cited by 106
Taveau, C., Chollet, C., Waeckel, L., Desposito, D., Bichet, D. G., Arthus, M.-F., Magnan, C., Philippe, E., Paradis, V., Foufelle, F., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3496-9 · Cited by 86
Kovacova, Z., Tharp, W. G., Liu, D., Wei, W., Xie, H., Collins, S., & Pratley, R. E. (2016) · Obesity · doi:10.1002/oby.21418 · Cited by 85
Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment
von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12594 · Cited by 73
Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues
Li, Y., Jiang, C., Wang, X., Zhang, Y., Shibahara, S., & Takahashi, K. (2007) · Peptides · doi:10.1016/j.peptides.2007.03.005 · Cited by 71
A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries
Niafar, M., Pourafkari, L., Porhomayon, J., & Nader, N. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3976-7 · Cited by 66
Impaired atrial natriuretic peptide-mediated lipolysis in obesity
Rydén, M., Bäckdahl, J., Petrus, P., Thorell, A., Gao, H., Coué, M., Langin, D., Moro, C., & Arner, P. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.222 · Cited by 64
Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males
Skov, J., Holst, J. J., Gøtze, J. P., Frøkiær, J., & Christiansen, J. S. (2014) · Endocrine Connections · doi:10.1530/ec-13-0087 · Cited by 63
von Scholten, B. J., Persson, F., Rosenlund, S., Eugen‐Olsen, J., Pielak, T., Faber, J., Hansen, T. W., & Rossing, P. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12884 · Cited by 60
Self-citationWong, H. K. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.364 · Cited by 51
Wu, A. H. B. (2013) · Current Heart Failure Reports · doi:10.1007/s11897-013-0156-6 · Cited by 45
Nylander, M., Frøssing, S., Kistorp, C., Faber, J., & Skouby, S. O. (2017) · Endocrine Connections · doi:10.1530/ec-16-0113 · Cited by 44
Self-citationHaufe, S., Kaminski, J., Utz, W., Haas, V., Mähler, A., Daniels, M. A., Birkenfeld, A. L., Lichtinghagen, R., Luft, F. C., Schulz-Menger, J., et al. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000573 · Cited by 41
Expression of adrenomedullin in adipose tissue of lean and obese women
Paulmyer‐Lacroix, O., Desbrière, R., Poggi, M., Achard, V., Alessi, M., Boudouresque, F., Ouafik, L., Vuaroqueaux, V., Labuhn, M., Dutourand, A., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02170 · Cited by 39
Plasma MR‐proADM Correlates to BMI and Decreases in Relation to Leptin After Gastric Bypass Surgery
Vila, G., Riedl, M., Maier, C., Struck, J., Morgenthaler, N. G., Handisurya, A., Prager, G., Ludvik, B., Clodi, M., & Luger, A. (2009) · Obesity · doi:10.1038/oby.2009.22 · Cited by 37
Taskin, M. I., Bulbul, E., Adali, E., Hismiogulları, A. A., & Inceboz, U. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.03.006 · Cited by 36
Karbek, B., Ozbek, M., Karakose, M., Topaloglu, O., Bozkurt, N., Cakır, E., Aslan, M., & Delibasi, T. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-31 · Cited by 35
Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity
Kistorp, C., Bliddal, H., Goetze, J. P., Christensen, R., & Faber, J. (2014) · BMC Obesity · doi:10.1186/s40608-014-0024-2 · Cited by 31
Self-citationAsferg, C. L., Andersen, U. B., Linneberg, A., Goetze, J. P., & Jeppesen, J. L. (2014) · Diabetic Medicine · doi:10.1111/dme.12411 · Cited by 26
Low plasma atrial natriuretic peptide: a new piece in the puzzle of polycystic ovary syndrome
Lauria, P. B. M., Del Puerto, H. L., Reis, A. M., Candido, A. L., & Reis, F. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2141 · Cited by 23
Deveer, M., Deveer, R., Basaran, O., Turkcu, U. O., Akbaba, E., Cullu, N., Turhan, N., Kucuk, M., & Kasap, B. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2375w · Cited by 22
Tzikas, S., Keller, T., Wild, P. S., Schulz, A., Zwiener, I., Zeller, T., Schnabel, R. B., Sinning, C., Lubos, E., Kunde, J., et al. (2013) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm-2012-0541 · Cited by 22
Lin, E., McCabe, E., Newton-Cheh, C., Bloch, K., Buys, E., Wang, T., & Miller, K. K. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.11.001 · Cited by 12
Letizia, C., Iacobellis, G., Caliumi, C., Leonetti, F., Cotesta, D., Ribaudo, M., Petramala, L., Cianci, R., Celi, M., D'Erasmo, E., et al. (2005) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2005-837519 · Cited by 11
Malin Nylander, S. F. (2015) · Journal of Obesity & Weight Loss Therapy · doi:10.4172/2165-7904.1000254 · Cited by 7
Self-citationPlasma adrenomedullin levels in patients with polycystic ovary syndrome
Ucar, B., Noyan, V., Caglayan, O., Yucel, A., & Sagsoz, N. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.02.119 · Cited by 5
Adrenomedullin: possible predictor of insulin resistance in women with polycystic ovary syndrome.
(2012) · PubMed · doi:10.3275/7872 · Cited by 5
Frøssing, S., Nylander, M., Aziz, M., Skouby, S. O., Kistorp, C., & Faber, J. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1202915 · Cited by 3
Self-citation
Research works printed but not linked: 44
- 2013, Low plasma atrial natriuretic peptide: a new piece in the puzzle of polycystic ovary syndrome, Journal of Clinical Endocrinology and Metabolism, 98, 4882, 10.1210/jc.2013-2141 · DOI · Paper page
- 2017, Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial, Diabetes, Obesity and Metabolism, 19, 901, 10.1111/dom.12884 · DOI · Paper page
- 2014, Copeptin, a surrogate marker for arginine vasopressin secretion, is associated with higher glucose and insulin concentrations but not higher blood pressure in obese men, Diabetic Medicine, 31, 728, 10.1111/dme.12411 · DOI · Paper page
- 2015, Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats, Diabetologia, 58, 1081, 10.1007/s00125-015-3496-9 · DOI · Paper page
- 2012, Effects of transdermal testosterone on natriuretic peptide levels in women: a randomized placebo-controlled pilot study, Fertility and Sterility, 97, 489, 10.1016/j.fertnstert.2011.11.001 · DOI · Paper page
- 2013, Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis., BMJ Open, 3, e001986, 10.1136/bmjopen-2012-001986 · DOI · Paper page
- 2015, Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome, European Journal of Obstetrics and Gynecology and Reproductive Biology, 189, 19, 10.1016/j.ejogrb.2015.03.006 · DOI · Paper page
- copeptin a unifying factor behind the metabolic syndrome of and https org, Plasma Journal Clinical Endocrinology Metabolism, 201196, 10.1210/jc.2010-2981 · DOI · Paper page
- 2004, Use and abuse of HOMA modeling, Diabetes Care, 27, 1487, 10.2337/diacare.27.6.1487 · DOI · Paper page
- 2015, Differential response of the natriuretic peptide system to weight loss and exercise in overweight or obese patients, Journal of Hypertension, 33, 1458, 10.1097/hjh.0000000000000573 · DOI · Paper page
- 2016, A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries, Archives of Gynecology and Obstetrics, 293, 509, 10.1007/s00404-015-3976-7 · DOI · Paper page
- 2016, Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes, Obesity, 24, 820, 10.1002/oby.21418 · DOI · Paper page
- 2005, Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay, Clinical Chemistry, 51, 1823, 10.1373/clinchem.2005.051110 · DOI · Paper page
- 2011, Influence of sex and hormone status on circulating natriuretic peptides, Journal of the American College of Cardiology, 58, 618, 10.1016/j.jacc.2011.03.042 · DOI · Paper page
- 2016, Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis., Oncotarget, 7, 33715, 10.18632/oncotarget.9553 · DOI · Paper page
- 2014, Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity, BMC Obesity, 1, 24, 10.1186/s40608-014-0024-2 · DOI · Paper page
- 2004, Impact of obesity on plasma natriuretic peptide levels, Circulation, 109, 594, 10.1161/01.cir.0000112582.16683.ea · DOI · Paper page
- 2000, Adrenomedullin, a multifunctional regulatory peptide, Endocrine Reviews, 21, 138
- 2015, The LIPT-Study: on risk markers of vascular thrombosis in polycystic ovary syndrome a randomized, double-blind, placebo-controlled study of the effect of liraglutide, Journal of Obesity and Weight Loss Therapy, 5, 254
- 2014, Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome, Journal of Ovarian Research, 7, 31, 10.1186/1757-2215-7-31 · DOI · Paper page
- 2015, Serum copeptin, pentraxin 3, anti-mullerian hormone levels with echocardiography and carotid artery intima-media thickness in adolescents with polycystic ovary syndrome, Journal of Clinical Medicine Research, 7, 989, 10.14740/jocmr2375w · DOI · Paper page
- 2013, GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure, Nature Medicine, 19, 567, 10.1038/nm.3128 · DOI · Paper page
- 2005, Acute hyperinsulinemia is associated with increased plasma adrenomedullin concentrations in uncomplicated obesity, Experimental and Clinical Endocrinology and Diabetes, 113, 171, 10.1055/s-2005-837519 · DOI · Paper page
- 2009, Plasma MR-proADM correlates to BMI and decreases in relation to leptin after gastric bypass surgery., Obesity, 17, 1184, 10.1038/oby.2009.22 · DOI · Paper page
- 2006, Plasma adrenomedullin levels in patients with polycystic ovary syndrome, Fertility and Sterility, 86, 942, 10.1016/j.fertnstert.2006.02.119 · DOI · Paper page
- 2017, Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential, Endocrine Connections, 6, 89, 10.1530/ec-16-0113 · DOI · Paper page
- 2013, Midregional pro-atrial natriuretic peptide in the general population/insights from the Gutenberg Health Study, Clinical Chemistry and Laboratory Medicine, 51, 1125
- 2014, Adrenomedullin and diabetes, World Journal of Diabetes, 5, 364, 10.4239/wjd.v5.i3.364 · DOI · Paper page
- 2015, Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment, Diabetic Medicine, 32, 343, 10.1111/dme.12594 · DOI · Paper page
- 1999, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp, Diabetes Care, 22, 1462, 10.2337/diacare.22.9.1462 · DOI · Paper page
- 2012, Adrenomedullin: possible predictor of insulin resistance in women with polycystic ovary syndrome, Journal of Endocrinological Investigation, 35, 553
- 2007, Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues, Peptides, 28, 1129, 10.1016/j.peptides.2007.03.005 · DOI · Paper page
- 2014, Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males, Endocrine Connections, 3, 11, 10.1530/ec-13-0087 · DOI · Paper page
- 2016, Atrial natriuretic peptide, copeptin and adrenomedullin levels in polycystic ovary syndrome: a case-control study, Gynecological Endocrinology, 33, 30
- 2016, Impaired atrial natriuretic peptide-mediated lipolysis in obesity, International Journal of Obesity, 40, 714, 10.1038/ijo.2015.222 · DOI
- 2010, Plasma copeptin and the risk of diabetes mellitus, Circulation, 121, 2102, 10.1161/circulationaha.109.909663 · DOI · Paper page
- 2006, Expression of adrenomedullin in adipose tissue of lean and obese women, European Journal of Endocrinology, 155, 177, 10.1530/eje.1.02170 · DOI
- 2015, Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes, Diabetes Care, 38, 132, 10.2337/dc14-1958 · DOI · Paper page
- 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, New England Journal of Medicine, 375, 311, 10.1056/nejmoa1603827 · DOI · Paper page
- 2016, Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial, Diabetes, Obesity and Metabolism, 18, 581, 10.1111/dom.12651 · DOI · Paper page
- 2013, Biological and analytical variation of clinical biomarker testing: implications for biomarker-guided therapy, Current Heart Failure Reports, 10, 434, 10.1007/s11897-013-0156-6 · DOI · Paper page
- 2014, Natriuretic peptides in cardiometabolic regulation and disease, Nature Reviews Cardiology, 11, 403, 10.1038/nrcardio.2014.64 · DOI · Paper page
- 2012, Adrenomedullin and cardiovascular diseases, JRSM Cardiovascular Disease, 1
- 2014, GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody, Endocrinology, 155, 1280, 10.1210/en.2013-1934 · DOI · Paper page
Cited by
Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics
Glueck, C. J., & Goldenberg, N. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.002 · Cited by 442
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933433 · Cited by 82
Austregésilo de Athayde De Hollanda Morais, B., Martins Prizão, V., de Moura de Souza, M., Ximenes Mendes, B., Rodrigues Defante, M. L., Cosendey Martins, O., & Rodrigues, A. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108834 · Cited by 68
Liao, C., Liang, X., Zhang, X., & Li, Y. (2023) · PLOS ONE · doi:10.1371/journal.pone.0289616 · Cited by 63
Goldberg, A., Graca, S., Liu, J., Rao, V., Witchel, S. F., Pena, A., Li, R., Mousa, A., Tay, C. T., Pattuwage, L., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13704 · Cited by 59
Metadata
- Authors
- Frøssing, S., Nylander, M., Kistorp, C., Skouby, S. O., & Faber, J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Frøssing, Signe
- Venue
- Endocrine Connections
- Publisher
- Bioscientifica
- Published
- 2018-01
- Volume
- 7
- Issue
- 1
- Pages
- 115-123
- ISSN
- 2049-3614 (ISSN-L)
- PMC
- PMC5754509
- OpenAlex
- W2781586249
- Semantic Scholar
- 47e1f74ed3ecbae5c0d49fbfa1a45b5523ada6a1
- Cited by
- 38
- References
- 46
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 10 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 2 · 2018: 1
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Endocrine Connections (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, polycystic ovary syndrome, atrial natriuretic peptide, adrenomedullin, copeptin, cardiovascular risk markers, GLP-1 receptor agonists, heart rate, diastolic blood pressure, insulin resistance, visceral fat, cardiovascular risk, overweight women, type 2 diabetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

